Atovaquone

Generic Name: Atovaquone

Brand Names: Malarone, Mepron

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉ClO_₃

CAS Number: 95233-18-4

Unique Ingredient Identifier: Y883P1Z2LT

Background: Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.

Indication: 主要用于治疗恶性疟原虫感染（对氯喹敏感或耐药者）；还可用于艾滋病患者合并卡氏肺囊虫病或弓形原虫性脑炎等治疗以及轻中度不能耐受复方磺胺药的肺孢子菌肺炎（PCP肺炎）。

Associated Conditions: Malaria caused by Plasmodium falciparum, Pneumocystis Jirovecii Pneumonia, Toxoplasma gondii encephalitis, Acute, uncomplicated Malaria caused by plasmodium falciparum, Mild Babesiosis, Mild Pneumocystis jiroveci pneumonia, Moderate Babesiosis, Moderate Pneumocystis jiroveci pneumonia

Associated Therapies: -

Clinical Trials

Atovaquone Combined with Radiation in Children with Malignant Brain Tumors

Phase 1

Recruiting

Conditions: High-grade Glioma
Medulloblastoma
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant

Interventions: Drug: Atovaquone
Radiation: Radiation Therapy

First Posted Date: 2024-10-03

Last Posted Date: 2024-11-07

Lead Sponsor: Emory University

Target Recruit Count: 18

Registration Number: NCT06624371

Locations: 🇺🇸
Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Healthcare of Atlanta: Scottish Rite, Atlanta, Georgia, United States

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian High Grade Serous Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma

Interventions: Drug: Atovaquone
Procedure: Biopsy
Procedure: Computed Tomography
Procedure: Paracentesis

First Posted Date: 2023-08-18

Last Posted Date: 2024-08-07

Lead Sponsor: Emory University

Target Recruit Count: 28

Registration Number: NCT05998135

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)

Early Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Atovaquone
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Gemtuzumab Ozogamicin

First Posted Date: 2018-06-26

Last Posted Date: 2024-11-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 26

Registration Number: NCT03568994

Locations: 🇺🇸
Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States
🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States

Atovaquone as Tumour HypOxia Modifier

Early Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atovaquone

First Posted Date: 2015-12-11

Last Posted Date: 2019-09-04

Lead Sponsor: University of Oxford

Target Recruit Count: 46

Registration Number: NCT02628080

Locations: 🇬🇧
Churchill Hospital, Oxford, Oxfordshire, United Kingdom

Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: Atovaquone
Drug: Atovaquone/proguanil HCL

First Posted Date: 2013-05-21

Last Posted Date: 2017-03-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT01858831

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

Phase 3

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 615

Registration Number: NCT00002340

Locations: 🇺🇸
Holmes Hosp, Cincinnati, Ohio, United States
🇺🇸
Hampton Roads Med Specialists, Hampton, Virginia, United States
🇺🇸
Bay Area AIDS Consortium, Tampa, Florida, United States

and more 2 locations

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

Not Applicable

Completed

Conditions: Toxoplasmosis, Cerebral
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00001994

Locations: 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸
Gathe, Joseph, M.D., Houston, Texas, United States

and more 19 locations

A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole

Phase 2

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00001996

Locations: 🇺🇸
UCI Med Ctr, Orange, California, United States
🇺🇸
Cedars Sinai Med Ctr, Los Angeles, California, United States
🇺🇸
AIDS Community Research Consortium, Redwood City, California, United States

and more 17 locations

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Not Applicable

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00001990

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

Not Applicable

Completed

Conditions: Pneumonia, Pneumocystis Carinii
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00001991

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy